Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00039130 · ClinicalTrials.gov registry record · Phase 2
Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
A Phase 2 study of Lymphoma and Leukemia, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 105
- Enrollment target
- 20
- Study locations
NCT00039130 is a Phase 2 study of Lymphoma and Leukemia that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 105 participants, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT00039130, a Phase 2 study of Lymphoma and Leukemia, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 105 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Monoclonal antibodies such as rituximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the numbers of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. Combining chemotherapy with rituximab and filgrastim may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining rituximab with chemotherapy and filgrastim in treating patients who have Burkitt's lymphoma or Burkitt's leukemia.
Interventions
- DRUG cyclophosphamide
- BIOLOGICAL rituximab
- DRUG dexamethasone
- BIOLOGICAL filgrastim
- DRUG cytarabine
Study Locations (20)
New York
- Roswell Park Cancer Institute - Buffalo
- Monter Cancer Center of the North Shore-LIJ Health System - Lake Success
- CCOP - North Shore University Hospital - Manhasset
- Don Monti Comprehensive Cancer Center at North Shore University Hospital - Manhasset
- Long Island Jewish Medical Center - New Hyde Park
Delaware
- Tunnell Cancer Center at Beebe Medical Center - Lewes
- CCOP - Christiana Care Health Services - Newark
Illinois
- University of Illinois Cancer Center - Chicago
- University of Chicago Cancer Research Center - Chicago
Iowa
- Hematology Oncology Associates of the Quad Cities - Bettendorf
- Holden Comprehensive Cancer Center at University of Iowa - Iowa City
Maryland
- Greenebaum Cancer Center at University of Maryland Medical Center - Baltimore
- Union Hospital Cancer Program at Union Hospital - Elkton
California
- Naval Medical Center - San Diego - San Diego
District of Columbia
- Walter Reed Army Medical Center - Washington D.C.
Indiana
- Fort Wayne Medical Oncology and Hematology - Fort Wayne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2002-05 |
| Est. Completion | 2014-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00039130
The ClinicalTrials.gov registry entry for NCT00039130 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (78% lower). The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00039130 reports 20 study locations spanning 12 distinct geographic areas - top geographies include New York, Delaware, Illinois.
Frequently Asked Questions
What is clinical trial NCT00039130 about?
NCT00039130 is a clinical study titled "Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia". RATIONALE: Monoclonal antibodies such as rituximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Colony-stimulating fa...
What is the current status of trial NCT00039130?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 105 participants. The study started on 2002-05. Estimated completion is 2014-10.
What conditions does trial NCT00039130 study?
This clinical trial studies the following conditions: Lymphoma, Leukemia.
What interventions are being tested in trial NCT00039130?
The interventions under investigation include: cyclophosphamide (DRUG), rituximab (BIOLOGICAL), dexamethasone (DRUG), filgrastim (BIOLOGICAL), cytarabine (DRUG).
Who is sponsoring clinical trial NCT00039130?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00039130 being conducted?
This trial has 20 study locations across California, Delaware, District of Columbia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.